全文获取类型
收费全文 | 232046篇 |
免费 | 30627篇 |
国内免费 | 9031篇 |
专业分类
耳鼻咽喉 | 1704篇 |
儿科学 | 1885篇 |
妇产科学 | 5229篇 |
基础医学 | 16640篇 |
口腔科学 | 2178篇 |
临床医学 | 19909篇 |
内科学 | 28838篇 |
皮肤病学 | 1480篇 |
神经病学 | 904篇 |
特种医学 | 8342篇 |
外国民族医学 | 253篇 |
外科学 | 35560篇 |
综合类 | 29716篇 |
现状与发展 | 38篇 |
一般理论 | 3篇 |
预防医学 | 10765篇 |
眼科学 | 113篇 |
药学 | 16699篇 |
141篇 | |
中国医学 | 5899篇 |
肿瘤学 | 85408篇 |
出版年
2024年 | 211篇 |
2023年 | 4615篇 |
2022年 | 6869篇 |
2021年 | 11557篇 |
2020年 | 11435篇 |
2019年 | 10280篇 |
2018年 | 9964篇 |
2017年 | 10265篇 |
2016年 | 11184篇 |
2015年 | 12950篇 |
2014年 | 19181篇 |
2013年 | 18625篇 |
2012年 | 15487篇 |
2011年 | 15720篇 |
2010年 | 11857篇 |
2009年 | 12112篇 |
2008年 | 12407篇 |
2007年 | 11637篇 |
2006年 | 10481篇 |
2005年 | 8493篇 |
2004年 | 6879篇 |
2003年 | 5751篇 |
2002年 | 4919篇 |
2001年 | 4467篇 |
2000年 | 3705篇 |
1999年 | 3021篇 |
1998年 | 2419篇 |
1997年 | 2134篇 |
1996年 | 1724篇 |
1995年 | 1786篇 |
1994年 | 1528篇 |
1993年 | 1156篇 |
1992年 | 1014篇 |
1991年 | 894篇 |
1990年 | 675篇 |
1989年 | 629篇 |
1988年 | 537篇 |
1987年 | 444篇 |
1986年 | 348篇 |
1985年 | 442篇 |
1984年 | 350篇 |
1983年 | 227篇 |
1982年 | 253篇 |
1981年 | 243篇 |
1980年 | 202篇 |
1979年 | 143篇 |
1978年 | 120篇 |
1977年 | 93篇 |
1976年 | 84篇 |
1975年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 17 毫秒
51.
宫颈癌严重威胁全球女性的生命健康,晚期宫颈癌治疗手段有限,5年生存率不到20%,是妇科肿瘤的巨大挑战。免疫治疗是晚期宫颈癌患者的重要治疗手段之一,包括免疫检查点抑制剂、治疗性疫苗和过继性T细胞免疫疗法等,但免疫治疗耐药性使部分患者无应答而效果不佳。因此,迫切需要深入研究和探讨免疫耐药的机制从而改善耐药,现归纳总结了近年有关宫颈癌中免疫耐药机制的相关研究,主要分为肿瘤内在因素和外在免疫环境改变等因素,并介绍针对免疫耐药提出的应对措施及进展。 相似文献
52.
Alicia C. McDonald PhD MPH Jeremy Gernand PhD Nathaniel R. Geyer DrPH Hongke Wu MD MPH Yanxu Yang MPH Ming Wang PhD 《Cancer》2022,128(9):1832-1839
53.
54.
《European journal of surgical oncology》2022,48(8):1713-1717
BackgroundLymphedema is a serious complication of axillary lymph node dissection (ALND) with an incidence rate of 20%. Simplified Lymphatic Microsurgical Preventing Healing Approach (SLYMPHA) is a safe and relatively simple method, which decreases incidence of lymphedema dramatically. Our initial study showed an 88% decrease in clinical lymphedema rate. In the initial study, we used arm circumference measurement for the diagnosis of lymphedema and median follow up was 15 months. The aim of this study was to confirm these results after a long-term follow up period and by using bioimpedance spectroscopy (L-Dex) technology in detecting lymphedema.Study designAll patients, undergoing ALND with or without SLYMPHA between January 2014 and November 2020 were included in the study. Patients with no postoperative L-Dex measurements were excluded. A L-Dex score outside the normal range (±10 L-Dex unit) or ≥10 L-Dex unit increase above patient's baseline was considered as lymphedema. The incidence of lymphedema was compared between patients with and without SLYMPHA.Results194 patients were included in the study. 57% of cohort underwent SLYMPHA. Mean follow-up time was 47 ± 37 months. Patients, who underwent SLYMPHA, had a significantly lower rate of lymphedema (16% vs 32%; p = 0.01; OR 0.4 [0.2–0.8]).ConclusionSLYMPHA is a safe and relatively simple method, which continued its efficacy after a long-term follow up period. It should be considered as an adjunct procedure to ALND for all patients during initial surgery. 相似文献
55.
56.
AimsOligometastatic disease (OMD) represents a spectrum of clinical scenarios and various classification systems have been proposed. Bone-only OMD can occur in patients with advanced prostate cancer and validated decision-making tools are needed to assist patient selection for metastasis-directed therapy. The aim of the present study was to determine the prognostic utility of a classification system for OMD.Materials and methodsA retrospective review was conducted of all patients with bone-only oligometastatic prostate cancer treated with stereotactic body radiotherapy (SBRT) since November 2011. SBRT was delivered using CyberKnife® and gantry-based linear accelerator platforms. All patients were classified into oligometastatic states based on the European Society for Radiotherapy and Oncology/European Organisation for Research and Treatment of Cancer (ESTRO/EORTC) classification system. Kaplan–Meier and Cox regression analyses were carried out to determine the prognostic utility of this classification system.ResultsIn total, 105 patients with 145 osseous metastases were treated over 119 sessions. The median follow-up after SBRT was 23 months (interquartile range 10–39.8). Twelve patients had died after a median time of 31 months. The 3-year metastatic progression-free survival was 23% (95% confidence interval 13–32) and the 3-year overall survival was 88% (95% confidence interval 80–96). Patients in a metachronous oligometastatic state were 4.50 (95% confidence interval 1.19–17.10, P = 0.03) times more likely to experience metastatic progression compared with those with synchronous oligometastases, and 6.69 (95% confidence interval 1.05–42.50, P = 0.04) times more likely to experience any failure. Hazard ratio magnitudes increased for patients in a repeat oligometastatic state. The multivariate model for both metastatic progression-free survival and failure-free survival found prostate-specific antigen doubling time <4 months (P = 0.002; P = 0.05) to independently predict for progression.ConclusionThe ESTRO/EORTC classification of OMD predicts for progression in patients treated with SBRT for bone-only oligometastatic prostate cancer at our institution. Further validation in prospective series over multiple tumour sites is needed. These characterisation factors should be assessed in patients considered for metastasis-directed therapy together with established prognostic features. 相似文献
57.
《European journal of surgical oncology》2022,48(3):694-702
ObjectivesTo describe our robotic Y intracorporeal neobladder (ICNB) technique and to report its post-operative complications and urodynamics (UD) findings.Subjectsand Methods: In this prospective study we enrolled patients affected by MIBC (T1-T4N0–N1M0) from 01/2017 to 06/2021 at our Centers. All the patients underwent robotic radical cystectomy (RARC) with Y–ICNB reconfiguration. Early and late complications were collected and classified according to Clavien-Dindo. Continence and potency at 1, 3, 6 and 12 months were evaluated. At the 3rd month of follow-up patients underwent UD. Finally, in a retrospective match paired analysis the functional outcomes of Y RARC patients were compared with a cohort of open Y radical cystectomy.Results45 patients were enrolled. Overall 30-day complications were observed in 25 (55,5%) patients and 30 to 90-days complications in 4 (8,9%). 9 patients (20%) had Clavien ≥3 complications. UDs revealed median neobladder capacity of 268 cc, with a median compliance of 13 ml/cm H20; the voiding phase showed a voiding volume and a post void residual (PVR) of 154 cc and 105 cc respectively. At 12 months of follow-up 4.4%, 15.5% and 4.4% of the patients experienced urge, stress and mix urinary incontinence respectively. The comparison between Y RARC and Y open RC revealed a higher neobladder capacity with open approach (p = 0.049) with subsequent better findings during the voiding phase in terms of maximum flow (p = 0.002), voiding volume (p = 0.001) and PVR (p = 0.01). Focusing on continence recovery, a slight trend in favor of RARC was shown without reaching the statistical significance.ConclusionsRobotic Y–ICNB is feasible and safe as shown by the low rate of postoperative complications. Satisfying UD functional outcomes are achievable, both during filling and voiding phase. 相似文献
58.
Georgios D. Lianos MD PhD Maximos Frountzas MD MPA PhD Dimitrios Schizas MD PhD Evangelos G. Baltagiannis MD George A. Alexiou MD PhD Christina Bali MD PhD Georgios K. Glantzounis MD PhD Michail Mitsis MD PhD Konstantinos Vlachos MD PhD 《Journal of surgical oncology》2023,127(1):7-10
During first outburst of COVID-19, several strategies had been applied for surgical oncology patients to minimize COVID-19 transmission. COVID-19 infection seemed to compromise survival and major complication rates of surgical oncology patients. However, survival, tumor progression and recurrence rates of surgical oncology patients were associated to the consequences of COVID-19 pandemic on their management. In addition, the severity of COVID-19 infections has been downgraded. Therefore, management of surgical oncology patients should be reconsidered. 相似文献
59.
60.
《Drug discovery today》2022,27(9):2551-2561
B cell lymphoma 2 (BCL2) overexpression in a range of human tumors is often related to chemotherapy resistance and poor prognosis. GC-rich regions upstream of the P1 promoter in human BCL2 can form G-quadruplex (G4) structures through the stacking of four Hoogsteen-paired guanine bases. Stabilizing the G4 fold implies the inhibition of BCL2 expression and, thus, small molecules that selectively bind to the G4 are promising anticancer candidates. In this review, we discuss the structural aspects, binding affinity, selectivity, and biological activity of well-characterized BCL2 G4 binding ligands in vitro and in vivo. We also explore future directions in the research and development of G4-based anticancer therapeutics. 相似文献